NASDAQ OMX

Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market Opportunities

Dela
  • Study designed to determine differential diagnosis in depression patients
  • Study designed to monitor patient data following pharmacological treatment

SYDNEY, Australia and MINNEAPOLIS, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions,  is pleased to announce the first prospective clinical trial with Mayo Clinic under a 5-year Master Clinical Trial Agreement that was signed in October of this year.  This initial study, undertakes the prospective diagnosis and longitudinal monitoring of both unipolar and bipolar depression, along with the depressive subtypes (melancholic and atypical).

The primary goal is to characterize longitudinal autonomic, circadian, and sleep patterns, as classified by the Medibio Analytics Platform (MAP), following the initiation of a standard pharmacological treatment for a new or recurrent, moderate-to-severe major depressive episode of both the unipolar and bipolar type.  Additionally, MAP will be used to characterize patterns unique to the bipolar type depression.

The research study team will be led by Mark A. Frye, M.D., at Mayo Clinic's Rochester campus. Dr. Frye, the chair of Mayo's Department of Psychiatry and Psychology, received his medical degree from the University of Minnesota and completed his psychiatric training at the UCLA Neuropsychiatric Institute. He completed a subsequent research fellowship in the Biological Psychiatry Branch at the National Institute of Mental Health (NIMH) in Bethesda, Maryland. While at NIMH, his area of research was focusing on the neurobiology of depression and bipolar disorder.

"We have been eager to get this initial study started with Dr. Frye and Mayo Clinic, as this kicks off our first of many collaborations in mental health between our organizations.  The importance of this study is to look at bipolar depression and differential diagnosis with our analytics platform, which can ultimately drive getting the right treatment to the right patient at the right time.  Mayo remains a leading academic center of excellence that the world looks to for innovative solutions to global problems," says Jack Cosentino, Medibio's CEO and Managing Director.

"The Mayo Clinic Depression Center has focused our research efforts on studies that have the potential to innovate our clinical practice; making a positive impact on patients' lives," says Dr. Frye.

It is estimated that 350M people worldwide suffer from depression. Depression is one of the leading causes of disability in the United States.  Two major challenges in the clinical practice of mood disorder is distinguishing major depressive disorder from bipolar depression and individualizing treatments for patients who struggle with depression. As treatment options markedly differ in these two mood disorders, biomarkers to help accurate diagnosis and guide treatment would be of tremendous clinical value.

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director
Medibio Limited
jack.cosentino@medibio.com.au
T: +1 (952) 465 4787

Australian Media Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

eGain to exhibit at Call Centre World 2018 in Berlin23.1.2018 12:30Pressmeddelande

Company will join forces with Cisco to showcase knowledge-infused, AI-guided omnichannel customer engagement at Europe's premier call centre conference SUNNYVALE, Calif. and NEWBURY, U.K., Jan. 23, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud customer engagement solutions, today announced that the company will showcase its award-winning digital engagement suite for the Cisco contact centre infrastructure-eGain Solve(TM) for Cisco Unified CCE(TM)-at CCW 2018 in Berlin, scheduled for February 26th through March 1st , 2018. Proven in world-class deployments, eGain Solve suite helps companies simultaneously elevate the customer experience (CX), business experience (BX), and agent experience (AX) to make digital transformation of experiences (DX) easy and successful. The solution dramatically improves metrics such as NPS (Net Promoter Score), CSAT (Customer Satisfaction), FCR (First-Contact Resolution), AHT (Average Handle Time), speed to agent competency, tra

Quinta do Lago: A resort that delivers year-round ROI23.1.2018 12:10Pressmeddelande

LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- A holiday home is not only somewhere to create treasured memories with family and friends, it can also represent a solid business investment. Accessibility, amenities, seasonal consistency and security are all likely to be key considerations when searching for a potential location, and Quinta do Lago scores highly across the board. Located just to the west of Faro Airport, the picturesque resort is part of the Algarve's Golden Triangle and easily accessible from most UK airports, as well as major European cities such as Paris, Madrid and Frankfurt. Accessibility is essential if holiday homes are to provide year-round return on investment (ROI), and Quinta do Lago is capable of attracting weekend holidaymakers and longer-term travellers alike. Fantastic leisure facilities ensure that the resort delivers year-round appeal. Golf, wellness services, award-winning restaurants and a multi-sports hub provide Quinta do Lago with seasonal consistency. F

AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia23.1.2018 04:44Pressmeddelande

TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, an investigational gene therapy for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease. The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan. AnGes anticipates being granted conditional approval under the regulatory scheme of "Approval with Conditions and Time Limit" for regenerative medicines. The review process is expected to take approximately one year. HGF plasmid has the potential to be one of the first gene therapy products to be approved for a non-genetic disease with chronic conditions. AnGes grants to Mitsubishi Tan

SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line23.1.2018 00:59Pressmeddelande

Boungou 80% Complete - Continues on Time, on Budget MONTREAL, Jan. 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports 2017 production of 206,400 ounces at an all-in sustaining cost of $943 per ounce. As a result, the Corporation has beat its revised production and met its cost guidance for the year. Mana In the fourth quarter, Mana produced 49,500 ounces of gold at a total cash cost1 of $667 per ounce and all-in sustaining cost2 of $987 per ounce Annual production of 206,400 ounces, slightly ahead of 2017 guidance of 190,000 to 205,000 ounces Total cash cost1 for 2017 of $655 per ounce All-in sustaining cost2 for 2017 of $943 per ounce, in line with guidance of $920 to $960 per ounce Gold sales of 205,300 ounces generated 2017 revenues of $259 million ($1,261 per ounce) Mining Operations Mana, Burkina Faso Three-month period Year ended December 31, ended December 31, 2017 2016 Variation 2017 2016 Variation Tonnes processed 653,500 714,200 (8%) 2,739,900 2,753,300 - He

Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30Pressmeddelande

VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti

Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54Pressmeddelande

PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com This announ

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum